tradingkey.logo

Novocure Ltd

NVCR
12.800USD
-0.020-0.16%
Close 10/31, 16:00ETQuotes delayed by 15 min
1.43BMarket Cap
LossP/E TTM

Novocure Ltd

12.800
-0.020-0.16%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Novocure Ltd

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Novocure Ltd's Score

Industry at a Glance

Industry Ranking
108 / 210
Overall Ranking
227 / 4621
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
24.688
Target Price
+83.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Novocure Ltd Highlights

StrengthsRisks
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 605.22M.
Overvalued
The company’s latest PE is -8.20, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 97.34M shares, decreasing 9.30% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 251.85K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 7.14, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 158.81M, representing a year-over-year increase of 5.62%, while its net profit experienced a year-over-year increase of 20.27%.

Score

Industry at a Glance

Previous score
7.14
Change
0

Financials

5.17

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.95

Operational Efficiency

9.77

Growth Potential

6.57

Shareholder Returns

7.22

Novocure Ltd's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -8.20, which is -27.08% below the recent high of -5.98 and -1539.21% above the recent low of -134.38.

Score

Industry at a Glance

Previous score
7.00
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 108/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 7.75, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Novocure Ltd is 23.50, with a high of 38.00 and a low of 14.50.

Score

Industry at a Glance

Previous score
7.75
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts
Buy
Current Rating
24.313
Target Price
+89.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Novocure Ltd
NVCR
8
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 4.58, which is lower than the Healthcare Equipment & Supplies industry's average of 6.55. Sideways: Currently, the stock price is trading between the resistance level at 14.15 and the support level at 12.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.83
Change
-0.25

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.343
Neutral
RSI(14)
40.796
Neutral
STOCH(KDJ)(9,3,3)
15.132
Oversold
ATR(14)
0.658
High Vlolatility
CCI(14)
-176.318
Sell
Williams %R
84.186
Oversold
TRIX(12,20)
0.075
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
13.212
Sell
MA10
13.620
Sell
MA20
13.772
Sell
MA50
13.109
Sell
MA100
13.990
Sell
MA200
16.806
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 87.06%, representing a quarter-over-quarter decrease of 9.59%. The largest institutional shareholder is The Vanguard, holding a total of 10.73M shares, representing 9.60% of shares outstanding, with 11.54% decrease in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
16.72M
+1.43%
The Vanguard Group, Inc.
Star Investors
10.73M
-4.45%
BlackRock Institutional Trust Company, N.A.
8.99M
+2.32%
Wyss (Hansjorg)
8.14M
--
Soleus Capital Management, L.P.
6.90M
+25.05%
Capital World Investors
6.38M
+22.38%
BlackRock Financial Management, Inc.
2.73M
+32.30%
State Street Investment Management (US)
2.68M
+3.45%
Geode Capital Management, L.L.C.
2.44M
-0.78%
Balyasny Asset Management LP
2.27M
+38.83%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 4.50, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.50
Change
0
Beta vs S&P 500 index
0.80
VaR
+6.01%
240-Day Maximum Drawdown
+67.38%
240-Day Volatility
+71.38%

Return

Best Daily Return
60 days
+8.20%
120 days
+8.76%
5 years
+68.45%
Worst Daily Return
60 days
-5.87%
120 days
-24.05%
5 years
-43.04%
Sharpe Ratio
60 days
+1.27
120 days
-0.74
5 years
-0.29

Risk Assessment

Maximum Drawdown
240 days
+67.38%
3 years
+90.83%
5 years
+95.17%
Return-to-Drawdown Ratio
240 days
-0.42
3 years
-0.30
5 years
-0.19
Skewness
240 days
+3.64
3 years
+2.59
5 years
+2.68

Volatility

Realised Volatility
240 days
+71.38%
5 years
+74.16%
Standardised True Range
240 days
+8.06%
5 years
+26.25%
Downside Risk-Adjusted Return
120 days
-84.51%
240 days
-84.51%
Maximum Daily Upside Volatility
60 days
+37.18%
Maximum Daily Downside Volatility
60 days
+29.59%

Liquidity

Average Turnover Rate
60 days
+1.48%
120 days
+1.18%
5 years
--
Turnover Deviation
20 days
+14.59%
60 days
+23.23%
120 days
-1.74%

Peer Comparison

Healthcare Equipment & Supplies
Novocure Ltd
Novocure Ltd
NVCR
6.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
Boston Scientific Corp
BSX
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Hologic Inc
Hologic Inc
HOLX
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI